Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib

Clinical Lung Cancer

Volumn 13, Issue 6, 2012, Pages 458-463

  Koizumi, Tomonobu ^a   Agatsuma, Toshihiko ^a   Ikegami, Kayoko ^a   Suzuki, Toshiro ^a   Kobayashi, Takashi ^a   Kanda, Shintaro ^a   Yoshikawa, Sumiko ^a   Kubo, Keishi ^a   Shiina, Takayuki ^a   Takasuna, Keiichirou ^b   Matsuo, Akemi ^c   Hayasaka, Muneharu ^d   Morikawa, Miwa ^e   Ameshima, Shingo ^e  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ina Chuo Hospital   (Japan)

^c Respiratory Division   (Japan)

^d National Hospital Organization Matsumoto Medical Center Matsumoto Hospital   (Japan)

^e UNIVERSITY OF FUKUI   (Japan)

Author keywords

Chemotherapy; EGFR mutation; Epidermal growth factor receptor tyrosine kinase inhibitor; Gefitinib responder; Non small cell lung cancer; Recharrenge

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; KAPLAN MEIER METHOD; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SKIN TOXICITY; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETREATMENT; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84867519411     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.01.006     Document Type: Article

References (24)

1. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
2. J.G. Paez, P.A. Jänne, J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
3. A. Inoue, T. Suzuki, T. Fukuhara Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J Clin Oncol 24 2004 3340 3346
4. S. Morita, I. Okamoto, K. Kobayashi Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations Clin Cancer Res 15 2009 4493 4498
5. K. Asami, T. Koizumi, K. Hirai Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group Study Clin Lung Cancer 12 2011 387 392
6. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
7. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 2 2010 121 128
8. J.Y. Wu, C.J. Yu, J.Y. Shih Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer Lung Cancer 67 2010 348 354
9. J.Y. Douillard, F.A. Shepherd, V. Hirsh Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 2010 744 752
10. D.H. Lee, K. Park, J.H. Kim Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy Clin Cancer Res 16 2010 1307 1314
11. J.A. Engelman, K. Zejnullahu, T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
12. S. Kobayashi, T.J. Boggon, T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
13. S. Yano, W. Wang, Q. Li Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res 68 2008 9479 9487
14. H. Asahina, S. Oizumi, A. Inoue Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib Oncology 79 2010 423 429
15. G. Giaccone, Y. Wang Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors Cancer Treat Rev 37 2011 456 464
16. G.J. Riely Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer J Thorac Oncol 3 2008 S146 S149
17. S. Yano, E. Nakataki, S. Ohtsuka Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases Oncol Res 15 2005 107 111
18. Y. Tomizawa, Y. Fujita, A. Tamura Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy Lung Cancer 68 2010 269 272
19. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
20. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 National Cancer Institute [Web site] http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm May 22, 2003 Accessed: March 1, 2011
21. H. Yokouchi, K. Yamazaki, I. Kinoshita Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer BMC Cancer 7 2007 51
22. A. Hata, N. Katakami, H. Yoshioka Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection Lung Cancer 74 2011 268 273
23. C. Bozzetti, M. Tiseo, C. Lagrasta Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites J Thorac Oncol 3 2008 18 22
24. A. Ushiki, K. Koizumi, N. Kobayashi Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome Jpn J Clin Oncol 39 2009 267 270